Posttranslational modification of vesicular stomatitis virus glycoprotein, but not JNK inhibition, is the antiviral mechanism of SP600125

Journal of Virology

Volumn 86, Issue 9, 2012, Pages 4844-4855

  Marozin, Sabrina ^a   Altomonte, Jennifer ^a   Apfel, Sibylle ^a   Dinh, Phat X ^b   De Toni, Enrico N ^c   Rizzani, Antonia ^c   Nüssler, Andreas ^a   Kato, Nobuyuki ^d   Schmid, Roland M ^a   Pattnaik, Asit K ^b   Ebert, Oliver ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTINEOPLASTIC AGENT; BETA INTERFERON; MITOGEN ACTIVATED PROTEIN KINASE; ONCOLYTIC VESICULAR STOMATITIS VIRUS; ONCOLYTIC VIRUS; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SPECIFICITY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN PROCESSING; VESICULAR STOMATITIS VIRUS; VIRUS ATTENUATION;

ANIMALS; ANTHRACENES; ANTIVIRAL AGENTS; CELL LINE; CRICETINAE; ENZYME ACTIVATION; HEPATOCYTES; HUMANS; INTERFERON TYPE I; MAP KINASE SIGNALING SYSTEM; MEMBRANE GLYCOPROTEINS; PROTEIN BIOSYNTHESIS; PROTEIN PROCESSING, POST-TRANSLATIONAL; TRANSCRIPTION, GENETIC; VESICULOVIRUS; VIRAL ENVELOPE PROTEINS; VIRION; VIRUS RELEASE;

RHABDOVIRIDAE; VESICULAR STOMATITIS VIRUS;

EID: 84861321834     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06649-11     Document Type: Article

References (61)

1. Altomonte J, et al. 2008. Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats. Hepatology 48:1864-1873.
2. Banerjee S, et al. 2008. Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream Akt/protein kinase B signaling pathway for insulin resistance. J. Virol. 82:2606-2612.
3. Bennett BL, et al. 2001. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. U. S. A. 98:13681-13686.
4. Bode AM, Dong Z. 2007. The functional contrariety of JNK. Mol. Carcinog. 46:591-598.
5. Bogoyevitch MA. 2006. The isoform-specific functions of the c-Jun Nterminal kinases (JNKs): differences revealed by gene targeting. Bioessays 28:923-934.
6. Cargnello M, Roux PP. 2011. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol. Mol. Biol. Rev. 75:50-83.
7. Ceballos-Olvera I, Chavez-Salinas S, Medina F, Ludert JE, del Angel RM. 2010. JNK phosphorylation, induced during dengue virus infection, is important for viral infection and requires the presence of cholesterol. Virology 396:30-36.
8. Chen F, Castranova V. 2009. Beyond apoptosis of JNK1 in liver cancer. Cell Cycle 8:1145-1147.
9. Clarke P, et al. 2004. JNK regulates the release of proapoptotic mitochondrial factors in reovirus-infected cells. J. Virol. 78:13132-13138.
10. Clarke P, Meintzer SM, Widmann C, Johnson GL, Tyler KL. 2001. Reovirus infection activates JNK and the JNK-dependent transcription factor c-Jun. J. Virol. 75:11275-11283.
11. Corcoran JA, et al. 2006. The p14 fusion-associated small transmembrane (FAST) protein effects membrane fusion from a subset of membrane microdomains. J. Biol. Chem. 281:31778-31789.
12. Dhanasekaran DN, Reddy EP. 2008. JNK signaling in apoptosis. Oncogene 27:6245-6251.
13. Du L, et al. 2004. Inhibition of cell proliferation and cell cycle progression by specific inhibition of basal JNK activity: evidence that mitotic Bcl-2 phosphorylation is JNK-independent. J. Biol. Chem. 279:11957-11966.
14. Ebert O, et al. 2003. Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res. 63:3605-3611.
15. Hanajiri K, et al. 2009. Echographic detection of diethylnitrosamineinduced liver tumors in rats and the effect of the intratumoral injection of an inhibitor of c-Jun N-terminal kinase. J. Gastroenterol. Hepatol. 24: 866-871.
16. Hassan M, Ghozlan H, Abdel-Kader O. 2005. Activation of c-Jun NH2-terminal kinase (JNK) signaling pathway is essential for the stimulation of hepatitis C virus (HCV) non-structural protein 3 (NS3)-mediated cell growth. Virology 333:324-336.
17. Heasley LE, Han SY. 2006. JNK regulation of oncogenesis. Mol. Cells 21:167-173.
18. Hirasawa K, et al. 2003. Effect of p38 mitogen-activated protein kinase on the replication of encephalomyocarditis virus. J. Virol. 77:5649-5656.
19. Holloway G, Coulson BS. 2006. Rotavirus activates JNK and p38 signaling pathways in intestinal cells, leading to AP-1-driven transcriptional responses and enhanced virus replication. J. Virol. 80:10624-10633.
20. Hu YB, Liu XY. 2009. Protective effects of SP600125 in a diet-induced rat model of non-alcoholic steatohepatitis. Scand. J. Gastroenterol. 44:1356-1362.
21. Huerta-Zepeda A, et al. 2008. Crosstalk between coagulation and inflammation during dengue virus infection. Thromb. Haemost. 99:936-943.
22. Hui L, Zatloukal K, Scheuch H, Stepniak E, Wagner EF. 2008. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J. Clin. Invest. 118:3943-3953.
23. Isaacson MK, Ploegh HL. 2009. Ubiquitination, ubiquitin-like modifiers, and deubiquitination in viral infection. Cell Host Microbe 18:559-570.
24. Iyoda K, et al. 2003. Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma. Cancer 97:3017-3026.
25. Kaneto H. 2005. The JNK pathway as a therapeutic target for diabetes. Expert Opin. Ther. Targets 9:581-592.
26. Kayser JP, Vallet JL, Cerny RL. 2004. Defining parameters for homologytolerant database searching. J. Biomol. Tech. 15:285-295.
27. Kerscher O, Felberbaum R, Hochstrasser M. 2006. Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu. Rev. Cell Dev. Biol. 22:159-180.
28. Keshet Y, Seger R. 2010. The MAP kinase signaling cascades: a system of hundreds of components regulates a diverse array of physiological functions. Methods Mol. Biol. 661:3-38.
29. Kluwe J, et al. 2010. Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Gastroenterology 138:347-359.
30. Kook SH, et al. 2008. Inhibition of c-Jun N-terminal kinase sensitizes tumor cells to flavonoid-induced apoptosis through down-regulation of JunD. Toxicol. Appl. Pharmacol. 227:468-476.
31. Kubo T, et al. 2011. Oncolytic vesicular stomatitis virus administered by isolated limb perfusion suppresses osteosarcoma growth. J. Orthop. Res. 29:795-800.
32. Kyriakis JM, Avruch J. 2001. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 81:807-869.
33. Lambert PJ, et al. 2007. Targeting the PI3K and MAPK pathways to treat Kaposi's-sarcoma-associated herpes virus infection and pathogenesis. Expert Opin. Ther. Targets 11:589-599.
34. Liu JR, et al. 2010. The c-Jun N-terminal kinase (JNK) inhibitor XG-102 enhances the neuroprotection of hyperbaric oxygen after cerebral ischaemia in adult rats. Neuropathol. Appl. Neurobiol. 36:211-224.
35. Liu M, et al. 2007. Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: synthesis and SAR studies. Bioorg. Med. Chem. Lett. 17:668-672.
36. Llovet JM, Bruix J. 2008. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48:1312-1327.
37. Lu YY, Chen TS, Wang XP, Qu JL, Chen M. 2010. The JNK inhibitor SP600125 enhances dihydroartemisinin-induced apoptosis by accelerat-ing Bax translocation into mitochondria in human lung adenocarcinoma cells. FEBS Lett. 584:4019-4026.
38. Marozin S, et al. 2008. Inhibition of the IFN-beta response in hepatocellular carcinoma by alternative spliced isoform of IFN regulatory factor-3. Mol. Ther. 16:1789-1797.
39. Mizutani T, Fukushi S, Saijo M, Kurane I, Morikawa S. 2005. JNK and PI3k/Akt signaling pathways are required for establishing persistent SARS-CoV infection in Vero E6 cells. Biochim. Biophys. Acta 1741:4-10.
40. Montagut C, Settleman J. 2009. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 283:125-134.
41. Mucha SR, et al. 2009. JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand. Gut 58:688-698.
42. Nagata H, et al. 2009. Inhibition of c-Jun NH2-terminal kinase switches Smad3 signaling from oncogenesis to tumor-suppression in rat hepatocellular carcinoma. Hepatology 49:1944-1953.
43. Noser JA, et al. 2007. The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: implication for the defective interferon response in cancer cells. Mol. Ther. 15:1531-1536.
44. Nussler A, et al. 2009. Regenerative medicine today: the holy grail of hepatocyte culturing and therapeutic use. Springer, Brighton, United Kingdom.
45. Oliere S, et al. 2008. Vesicular stomatitis virus oncolysis of T lymphocytes requires cell cycle entry and translation initiation. J. Virol. 82:5735-5749.
46. Pleschka S. 2008. RNA viruses and the mitogenic Raf/MEK/ERK signal transduction cascade. Biol. Chem. 389:1273-1282.
47. Roberts PJ, Der CJ. 2007. Targeting the Raf-MEK-ERK mitogenactivated protein kinase cascade for the treatment of cancer. Oncogene 26:3291-3310.
48. Salsman J, Top D, Barry C, Duncan R. 2008. A virus-encoded cell-cell fusion machine dependent on surrogate adhesins. PLoS Pathog. 4:e1000016.
49. Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV. 1997. Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 236:54-58.
50. Schwartz DC, Hochstrasser M. 2003. A superfamily of protein tags: ubiquitin, SUMO and related modifiers. Trends Biochem. Sci. 28:321-328.
51. Shin EC, et al. 2002. Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis, and the resistance is abolished by cisplatin. Exp. Mol. Med. 34:114-122.
52. Shinozaki K, Ebert O, Woo SL. 2005. Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV. Hepatology 41:196-203.
53. Shinozaki K, et al. 2004. Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus. Mol. Ther. 9:368-376.
54. Si X, et al. 2005. Stress-activated protein kinases are involved in coxsackievirus B3 viral progeny release. J. Virol. 79:13875-13881.
55. Wang Y, Pernet O, Lee B. 2012. Regulation of the nucleocytoplasmic trafficking of viral and cellular proteins by ubiquitin and small ubiquitinrelated modifiers. Biol. Cell 104:121-138.
56. Wei L, Zhu Z, Wang J, Liu J. 2009. JNK and p38 mitogen-activated protein kinase pathways contribute to porcine circovirus type 2 infection. J. Virol. 83:6039-6047.
57. Weston CR, Davis RJ. 2007. The JNK signal transduction pathway. Curr. Opin. Cell Biol. 19:142-149.
58. Whitt MA, Zagouras P, Crise B, Rose JK. 1990. A fusion-defective mutant of the vesicular stomatitis virus glycoprotein. J. Virol. 64:4907-4913.
59. Wimmer P, Schreiner S, Dobner T. 2012. Human pathogens and the host cell SUMOylation system. J. Virol. 86:642-654.
60. Yu JH, Lin BY, Deng W, Broker TR, Chow LT. 2007. Mitogen-activated protein kinases activate the nuclear localization sequence of human papillomavirus type 11 E1 DNA helicase to promote efficient nuclear import. J. Virol. 81:5066-5078.
61. Zapata HJ, Nakatsugawa M, Moffat JF. 2007. Varicella-zoster virus infection of human fibroblast cells activates the c-Jun N-terminal kinase pathway. J. Virol. 81:977-990.